Chemoenzymatic glycan editing for deciphering biological functions of glycans
化学酶聚糖编辑破译聚糖的生物学功能
基本信息
- 批准号:10329937
- 负责人:
- 金额:$ 76.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AffinityAutoimmune DiseasesBindingBinding ProteinsBiological ProcessCell CommunicationCell physiologyCell surfaceCellsDevelopmentDisease ProgressionEngineeringEnvironmentFDA approvedFucoseGenomeGlycoconjugatesGlycoproteinsGoalsImmuneImmune System DiseasesImmune checkpoint inhibitorImmune signalingImmunoglobulinsImmunotherapyIn SituLabelLectinLigandsMalignant NeoplasmsMediatingMetabolicMethodsModalityModificationMolecularMolecular Biology TechniquesMonosaccharidesN-acetyllactosamineNatural Killer CellsOligosaccharidesOrganismPatientsPolysaccharidesProductionPropertyRecombinantsRoleSialic AcidsSignal TransductionSpecificityStructureT-LymphocyteTherapeutic AgentsTumor ImmunityVaccinationVisualizationanti-CTLA4anti-PD-1basecheckpoint inhibitioncytokinecytotoxicexhaustionglycosylationglycosyltransferasehuman diseaseimmune activationimmunoregulationinterestnovelnovel therapeuticsreceptorreceptor bindingresponsesialic acid binding Ig-like lectinsugar nucleotidetool
项目摘要
PROJECT SUMMARY/ABSTRACT
Cell-surface glycans participate in numerous biological processes, including signal transduction, cell-cell
communication and development. Aberrant glycosylation is a hallmark of human disease. At a molecular level,
glycans represent the first points of contact between cells. However, not directly encoded in the genome, these
biomolecules are challenging to study using molecular biology techniques alone. Metabolic oligosaccharide
engineering (MOE) developed in late 1990’s has revolutionized the way for the labeling and visualization of
glycans in living organisms. In this method, cells’ own glycan biosynthetic machinery is hijacked to incorporate
unnatural monosaccharides with linkage promiscuity.
Complementary to MOE, chemoenzymatic glycan editing has emerged as a valuable tool to probe and
modify glycan structures within a cellular environment. Unlike MOE, chemoenzymatic glycan modification
utilizes recombinant glycosyltransferases to transfer natural or unnatural monosaccharides with novel functions
from activated nucleotide sugars to glycoconjugates on the cell surface with linkage specificity. For these
reasons, chemoenzymatic glycan modification provides a facile and more precise way for probing the function
of glycans in their native environments.
Building upon our successful application of chemoenzymatic glycan editing, in the next five years we will
expand our chemoenzymatic tool kits to study glycans’ cellular functions with a focus on the special roles of N-
acetyllactosamine (LacNAc), fucose and sialic acid in immune regulation. Cell-surface LacNAc mediates
ligand-receptor binding and sets a threshold for initiating the downstream signaling for immune cell activation.
LacNAc residues are dynamically modified by sialic acid and/or fucose. However, the specific roles of these
modifications in immune regulation and disease progression remain obscure.
We are particularly interested in finding out: (1) if changes in LacNAc and fucosylation status can serve
as glycan signatures of T cell exhaustion during which T cells gradually lose their cytokine production,
proliferation and cytotoxic capacity; (2) Can cell-surface in situ LacNAc fucosylation be used to boost the
efficacy of antitumor immunity of T cells and NK cells? In parallel, we will develop chemoenzymatic tools for
profiling sialylated glycoprotein ligands of Siglecs (sialic acid-binding immunoglobulin-type lectins) and for the
identification of unnatural, high-affinity and specific ligands to interrogate Siglec functions.
Through these studies, we will gain a deeper understanding of how LacNAc, fucose and sialic acid are
involved in the regulation of the immune cell activation, effector function and exhaustion. Tools developed in
this project can also be used to study other types of glycans and their interactions with glycan binding proteins.
项目总结/摘要
细胞表面聚糖参与许多生物学过程,包括信号转导、细胞-细胞
沟通与发展。异常糖基化是人类疾病的标志。在分子水平上,
聚糖代表细胞之间的第一接触点。然而,这些基因不是直接编码在基因组中,
单独使用分子生物学技术来研究生物分子具有挑战性。代谢寡糖
在20世纪90年代后期发展起来的MOE(MoE)已经彻底改变了标记和可视化的方式,
生物体内的聚糖。在这种方法中,细胞自身的聚糖生物合成机制被劫持,
具有键混杂性的非天然单糖。
作为莫伊的补充,化学酶聚糖编辑已经成为探测和分析聚糖的有价值的工具。
修饰细胞环境中的聚糖结构。与莫伊不同,化学酶聚糖修饰
利用重组糖基转移酶转移具有新功能的天然或非天然单糖
从活化的核苷酸糖到细胞表面上具有连接特异性的糖缀合物。为这些
因此,化学酶聚糖修饰提供了一种简便和更精确的方法来探测功能,
在它们的自然环境中。
在我们成功应用化学酶聚糖编辑的基础上,在未来五年内,我们将
扩展我们的化学酶工具包,以研究聚糖的细胞功能,重点是N-
乙酰乳糖胺(LacNAc)、岩藻糖和唾液酸在免疫调节中的作用。细胞表面LacNAc介导
配体-受体结合,并设定用于启动免疫细胞活化的下游信号传导的阈值。
LacNAc残基被唾液酸和/或岩藻糖动态修饰。然而,这些具体的作用
免疫调节和疾病进展的改变仍然不清楚。
我们特别感兴趣的是发现:(1)LacNAc和岩藻糖基化状态的变化是否可以
作为T细胞耗竭的聚糖标志,在此期间T细胞逐渐失去其细胞因子产生,
(2)细胞表面原位LacNAc岩藻糖基化是否可用于增强细胞增殖和细胞毒能力?
T细胞和NK细胞的抗肿瘤免疫效力?同时,我们将开发化学酶工具,
分析Siglecs的唾液酸化糖蛋白配体(唾液酸结合免疫球蛋白型凝集素)和Siglecs的唾液酸化糖蛋白配体(唾液酸结合免疫球蛋白型凝集素),
鉴定非天然、高亲和力和特异性配体以询问Siglec功能。
通过这些研究,我们将更深入地了解LacNAc、岩藻糖和唾液酸是如何与
参与调节免疫细胞活化、效应子功能和耗竭。开发工具
该项目也可用于研究其他类型的聚糖及其与聚糖结合蛋白的相互作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peng Wu其他文献
Peng Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peng Wu', 18)}}的其他基金
Chemoenzymatic glycan editing for deciphering biological functions of glycans
化学酶聚糖编辑破译聚糖的生物学功能
- 批准号:
10555320 - 财政年份:2021
- 资助金额:
$ 76.42万 - 项目类别:
Chemoenzymatic glycan editing for deciphering biological functions of glycans
化学酶聚糖编辑破译聚糖的生物学功能
- 批准号:
10799053 - 财政年份:2021
- 资助金额:
$ 76.42万 - 项目类别:
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
使用化学酶方法探索 Siglec-聚糖配体相互作用
- 批准号:
10297728 - 财政年份:2021
- 资助金额:
$ 76.42万 - 项目类别:
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
使用化学酶方法探索 Siglec-聚糖配体相互作用
- 批准号:
10621946 - 财政年份:2021
- 资助金额:
$ 76.42万 - 项目类别:
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
使用化学酶方法探索 Siglec-聚糖配体相互作用
- 批准号:
10417251 - 财政年份:2021
- 资助金额:
$ 76.42万 - 项目类别:
Chemical Tools for Studying Fucosylated Glycans
用于研究岩藻糖基化聚糖的化学工具
- 批准号:
9320789 - 财政年份:2016
- 资助金额:
$ 76.42万 - 项目类别:
Chemical Tools for Studying Fucosylated Glycans
用于研究岩藻糖基化聚糖的化学工具
- 批准号:
9105947 - 财政年份:2016
- 资助金额:
$ 76.42万 - 项目类别:
Chemoenzymatic methods for the detection of cell-surface glycans
检测细胞表面聚糖的化学酶法
- 批准号:
8964803 - 财政年份:2015
- 资助金额:
$ 76.42万 - 项目类别:
Chemical tools for studying fucosylated glycans
研究岩藻糖基化聚糖的化学工具
- 批准号:
8535787 - 财政年份:2010
- 资助金额:
$ 76.42万 - 项目类别:
Chemical tools for studying fucosylated glycans
研究岩藻糖基化聚糖的化学工具
- 批准号:
8326225 - 财政年份:2010
- 资助金额:
$ 76.42万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Operating Grants
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 76.42万 - 项目类别:














{{item.name}}会员




